No abstract

The use of divazа resulted in clinical improvement and normalization of markers of endothelial dysfunction as well.

The paper presents results of clinical and laboratory investigation of 106 patients with chronic brain ischemia (CBI) I—II stages, included detection levels of circulating desquamated endothelial cells, endothelin-1, autoantibodies to encephalitogenic protein, neuron-specific enolase and protein S100. Reliable changes of immune status as well as signs of endothelium dysfunction progressed with stage of CBI. Direct correlation between intensity of endothelium dysfunction and activity of neurodegererative process in brain was revealed.

The paper presents results of clinical and laboratory investigation of 106 patients with chronic brain ischemia (CBI) I-II stages (44 males and 62 females). The age of examined patients varied from 38 to 67 years (mean age was 55,6 ± 2,2). The diagnosis of CBI was estimated according to the generally accepted criteria. Results of laboratory investigation of 22 practically healthy people (10 males and 12 females) served as control. The age of control group varied from 35 to 64 years (mean age was 53,2 ± 2,1). Laboratory diagnostics included detection levels of circulating endothelial cells, autoantibodies to encephalitogenic protein, neuron-specific enolase and protein S-100. Reliable changes of immune status as well as signs of endothelium dysfunction was revealed. These indices are expressed in patients with CBI II stage. Direct correlation between intensity of endothelium dysfunction and activity of autoimmune aggression in brain was revealed.

Fahr disease is a rare hereditary or sporadic neurological condition characterized by bilateral calcium deposition in the basal ganglia, dentate nuclei of cerebellum, and subcortical white matter. We can also distinguish Farh syndrome when its etiology is associated with the disorder of calcium metabolism, mitochondriopathies, cerebrum neoplasms, infections, inflammatory diseases of the nervous system, and injuries. The most common manifestations in patients with calcification of the basal ganglia of cerebrum are neurological and/or psychiatric disorders of varying severity. The clinical manifestation of the disease can occur at different ages, but mainly in young and middle-aged adults. However, some patients remain asymptomatic throughout their lives. The main clinical manifestations of the disease are extrapyramidal and movement disorders, emotional and cognitive impairments. At the same time, the correspondence of the form and severity of neurological conditions and the nature of calcification of the basal ganglia is rare. Currently, the treatment strategy for Fahr disease is based on symptomatic therapy and correction of etiological factors in Fahr syndrome. There is information about the reversibility of the calcification process and the complete restoration of mental functions in the early diagnosis and treatment of Fahr syndrome.